Cas:261953-36-0 6-Iodo-1H-indazole manufacturer & supplier

Chemical Name:6-Iodo-1H-indazole

CAS.NO:261953-36-0

Synonyms:INDAZOLE,6-IODO;6-Iodoindazole;1H-Indazole, 6-iodo-;6-Iodo-1H-indazole;T56 BMNJ HI;1H-Indazole,6-iodo

Molecular Formula:C₇H₅IN₂

Molecular Weight:244.033

HS Code:2933990090

Physical and Chemical Properties:

Melting point:207.0 to 211.0 °C

Boiling point:358.2±15.0 °C at 760 mmHg

Density:2.1±0.1 g/cm3

Index of Refraction:1.788

PSA:28.68000

Exact Mass:243.949738

LogP:2.85

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like INDAZOLE,6-IODO chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Indazole,6-iodo physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Iodo-1H-indazole Use and application,1H-Indazole, 6-iodo- technical grade,usp/ep/jp grade.

Related News: Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 6-Iodo-1H-indazole manufacturer CROS NT built up its own biometric services portfolio: clinical data management, biostatistics, statistical programming and medical writing, through a series of acquisitions in the early 2010s. In 2013, CROS NT established a foothold in the U.S. with its purchase of Stat-Tech Services, which had a presence in the medical devices sector. CROS NT followed up the next year with its buy of biometrics services provider MDSL International to broaden its U.K. branch. 6-Iodo-1H-indazole supplier This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 6-Iodo-1H-indazole vendor Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 6-Iodo-1H-indazole factory This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care.